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Purpose: Use of lipid nanoemulsions as carriers of drugs for therapeutic or diagnostic   purposes 
has been increasingly studied. Here, it was tested whether modifications of core particle 
  constitution could affect the characteristics and biologic properties of lipid nanoemulsions. 
Methods: Three nanoemulsions were prepared using cholesteryl oleate, cholesteryl stearate, or 
cholesteryl linoleate as main core constituents. Particle size, stability, pH, peroxidation of the 
nanoemulsions, and cell survival and uptake by different cell lines were evaluated.
Results: It was shown that cholesteryl stearate nanoemulsions had the greatest particle 
size and all three nanoemulsions were stable during the 237-day observation period. The 
pH of the three nanoemulsion preparations tended to decrease over time, but the decrease 
in pH of cholesteryl stearate was smaller than that of cholesteryl oleate and cholesteryl 
linoleate. Lipoperoxidation was greater in cholesteryl linoleate than in cholesteryl oleate 
and cholesteryl stearate. After four hours’ incubation of human umbilical vein endothelial 
cells (HUVEC) with nanoemulsions, peroxidation was minimal in the presence of choles-
teryl oleate and more pronounced with cholesteryl linoleate and cholesteryl stearate. In 
contrast, macrophage incubates showed the highest peroxidation rates with cholesteryl oleate. 
Cholesteryl linoleate induced the highest cell peroxidation rates, except in macrophages. 
Uptake of cholesteryl oleate nanoemulsion by HUVEC and fibroblasts was greater than 
that of cholesteryl linoleate and cholesteryl stearate. Uptake of the three nanoemulsions by 
monocytes was equal. Uptake of cholesteryl oleate and cholesteryl linoleate by macrophages 
was negligible, but macrophage uptake of cholesteryl stearate was higher. In H292 tumor 
cells, cholesteryl oleate showed the highest uptakes. HUVEC showed higher survival rates 
when incubated with cholesteryl stearate and smaller survival with cholesteryl linoleate. 
H292 survival was greater with cholesteryl stearate.
Conclusion: Although all three nanoemulsion types were stable for a long period, considerable 
differences were observed in size, oxidation status, and cell survival and nanoemulsion uptake 
in all tested cell lines. Those differences may be helpful in protocol planning and interpretation 
of data from experiments with lipid nanoemulsions.
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Introduction
The use of nanoemulsions as drug delivery vehicles for the treatment of proliferative 
inflammatory diseases, such as cancer and atherosclerosis, has been increasingly 
studied.1–3 In search of more efficient drug delivery devices, the systematic modifica-
tion of the composition of those nanoemulsion systems to optimize the pharmacologic 
properties of the drug-vehicle association is an important research pathway.International Journal of Nanomedicine 2010:5
H O
O H
H H
H
H
O
O
H HH
H
H
H
H
H
O
O
H
HH
H
A
B
C
Figure 1 chemical structure of the cholesteryl esters used in the making of the nanoemulsions: A) cholesteryl oleate (18:1). B) cholesteryl linoleate (18:2). C) cholesteryl 
stearate (18:0).
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In previous studies, we have been showing that   cholesteryl 
ester-rich   nanoemulsions resembling the structure of lipopro-
teins can function as drug-targeting devices4–6 to carry drugs to 
tumors7 or atheromatous lesions.8   Nonprotein nanoemulsions 
resembling low-density lipoproteins (LDL) can pick up apoli-
poprotein E (apo E) in contact with plasma and bind to LDL 
receptors using this apolipoprotein as a ligand.9 The properties 
of LDL or other lipoprotein-binding receptors are interesting 
in terms of drug delivery. Because lipids must be disposable 
for the building of new membranes required by the accelerated 
mitosis rates in many pathologic   conditions, those receptors are 
frequently overexpressed, with   endowment of a potent target-
ing mechanism. Those nanoemulsions have been constructed 
with cholesteryl oleate as a particle core and egg lecithin as 
the surface enveloping layer. Minor amounts of triolein and 
free cholesterol were included in the composition.
The aim of this study was to investigate whether the 
degree of saturation of the acyl radicals of cholesteryl 
esters that make up the nanoemulsion core may influence 
the   physical and biologic properties of nanoemulsions. 
  Substitution in the   composition of the nanoemulsions of three 
different   cholesteryl esters with the same acyl chain length, 
namely oleate (18:1), linoleate (18:2), and stearate (18:0), 
the   chemical structures of which are shown in Figure 1, may 
influence the stability and peroxidation of nanoemulsion 
lipids and uptake by different cell lines. Survival of the cells 
upon coincubation with the three nanoemulsion cholesteryl 
esters was also examined. Results show that compositional 
changes in respect to cholesteryl ester molecular species can 
alter the biologic properties of the nanoemulsions.
Methods
Materials
The lipids were purchased from Sigma Chemical Company 
(St. Louis, MO). Cholesteryl [1–14C] oleate was purchased 
from Amersham (Little Chalfont, Buckinghamshire, UK). All 
the chemicals and solvents used in the study were of analytic 
grade and purchased from Sigma Chemical Company.
Preparation of artificial nanoemulsions
The artificial nanoemulsions were prepared according to 
the method described by Ginsburg et al10 and modified by 
  Maranhão et al.11 A lipid mixture composed of 40 mg choles-
teryl oleate, 20 mg egg phosphotidylcholine, 1 mg triolein, and International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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0.5 mg free cholesterol was dissolved in chloroform:methanol 
(2:1) and dispensed into vials. For the nanoemulsion with dif-
ferent cholesteryl ester species, in place of cholesteryl oleate, 
we used cholesteryl linoleate or cholesteryl stearate. The mix-
ture was dried under a nitrogen stream followed by overnight 
vacuum desiccation at 4°C to remove residual solvents. The 
dried lipids were resuspended in 10 mL of tris-HCl 0.01 M buf-
fer at pH 8.0 and the suspension was emulsified by prolonged 
ultrasonic irradiation for 180 minutes in a nitrogen atmosphere 
and with a controlled temperature. The emulsified lipid suspen-
sion was then transferred to clean tubes and ultracentrifugated at 
195,000 g for 30 minutes at 4°C. The supernatant was removed 
by aspiration with a needle. Solid KBr was added to the remain-
ing solution for density adjustment to 1.21 g/mL. A second 
ultracentrifugation step was then performed at 195,000 g for 
120 minutes at 4°C. The nanoparticles were recovered by 
aspiration and dialyzed overnight in tris-HCl buffer at a pH 
8.0 for KBr removal. The nanoemulsion was passed through 
a 0.22 µm Millipore™ filter (Millipore Inc., Billerica, MA). 
Trace amounts of cholesteryl [1-14C] oleate were added to the 
initial solution.
composition of nanoemulsion 
formulations
The composition of cholesteryl oleate, cholesteryl linoleate, 
and cholesteryl stearate nanoemulsion was determined after 
lipid extraction by the Folch method, resolution of the lipid 
components by thin-layer chromatography, iodine staining, 
and determination of the density of bands using a model 
L.PIX transluminator (Loccus, São Paulo, Brazil).
Particle size, polydispersity, and zeta 
potential analysis
Each batch of nanoemulsions was characterized for particle 
size, polydispersity, and zeta potential by the dynamic light 
scattering method using a ZetaPALS Zeta Potential Analyzer 
(Brookhaven Instruments, Holtsville, NY). For size measure-
ment, nanoemulsion samples (35 µL) were diluted in 2.0 mL 
tris-HCl 0.01 M buffer at pH 8.05, ie, the same buffer that was 
used in the making of the nanoemulsions. At the time of particle 
size determination, average count rate was   maintained between 
50–200 kcps to achieve   reproducibility. The mean effective 
hydrodynamic diameter of the oil droplets on log-normal size 
distribution mode was considered for comparative evaluation. 
For zeta potential measurements, the nanoemulsion samples 
(45 µL) were diluted to 1.5 mL of KCl 1.0 mM. Hydrodynamic 
diameter, polydispersity, and zeta potential were reported as 
the average of two measurements performed at 25°C. For 
stability studies, all samples were kept at 4°C over a period 
of 240 days, and particle size and phase Doppler interfer-
ometry measurements were undertaken every 15 days. Zeta 
potential measurements were performed on days 1 and 210 
after manufacture.
ph analysis
Measurements of the pH of the nanoemulsions were per-
formed using a digital pH meter (Digimed, São Paulo, 
Brazil). For stability studies, all samples were kept at 4°C 
over a period of 240 days and the pH measurements were 
undertaken every 15 days.
Lipid peroxidation analysis
The lipid peroxidation of each nanoemulsion was measured 
by the thiobarbituric acid reactive substances (TBARS) 
  method.12 For stability studies, all samples were kept at 4°C 
over a period of 240 days and the lipid peroxidation measure-
ments were undertaken every 15 days.
cell uptake in the nanoemulsions
Human umbilical vein endothelial cells (HUVEC) were 
cultured in M-199 medium containing 20% fetal bovine 
serum. H292 (mucoepidermoid pulmonary carcinoma) and 
THP-1 (a human monocytic leukemia cell line), referred 
to here as monocytes and fibroblasts, were cultured in 
  RPMI-1640 containing 20% fetal bovine serum and all cells 
were used from passages four or five. The THP-1-monocytes 
was differentiated in THP-1-macrophages using 50 nM of 
phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) by 
24 hours. The cells were plated at 5 × 105 grown confluence, 
and 4 mL of medium with fetal bovine serum were added 
followed by 24 hours of incubation at 36°C. After 24 hours, 
the medium was changed to medium   lipoprotein-deficient 
serum to overexpress the receptors. After 24 hours of incu-
bation,   lipoprotein-deficient serum medium was   substituted 
with medium containing fetal bovine serum. All cell 
lines were incubated with cholesteryl oleate,   cholesteryl 
linoleate, and   cholesteryl stearate in concentrations rang-
ing from 0.15 mg/mL to 5.0 mg/mL for four hours. At 
the end of   incubation, the supernatant was collected for 
TBARS analyses. The cells were washed three times with 
  phosphate-buffered saline. The cells were harvested from the 
culture dish by treatment with a trypsin solution 0.02% and 
centrifuged for five minutes at 4°C. The cell pellets were soni-
cated and stored at tubes with scintillation solution (Packard 
BioScience, Groeningen, The Netherlands). The cell uptake 
was measured by radioactive counting of the cell lysate 
in a scintillation solution using a Packard 1600 TR model International Journal of Nanomedicine 2010:5
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Figure 2 stability of the three different nanoemulsions, cO (circles), cL (triangles), and cs (squares), as observed during 237 days, in respect to a) size, b) polydispersity, 
c) ph, and d) lipid peroxidation evaluated by the TBArs method. Data are expressed as means ± sD of two samples. 
Abbreviations: cO, cholesteryl oleate; cL, cholesteryl linoleate; cs, cholesteryl stearate; sD, standard deviation; TBArs, thiobarbituric acid reactive substances.
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Liquid Scintillation Analyzer (Palo Alto, CA). The protein 
  concentration was determined by Bradford assay.13
Lipid peroxidation of the  
nanoemulsion-cell incubates
After four hours of cholesteryl oleate, cholesteryl linoleate, 
and cholesteryl stearate nanoemulsion incubation with cells, 
100 µL of solely culture medium was collected for lipid 
peroxidation analysis14 by the TBARS method.12
cell survival upon incubation  
with nanoemulsions
The HUVEC and H292 cell lines were incubated with cho-
lesteryl oleate, cholesteryl linoleate, and cholesteryl stearate 
for four hours in 96-well plates at concentrations ranging 
from 0.15 mg/mL to 5.0 mg/mL. The number of viable cells 
was estimated by the MTT assay (3-[4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium-bromide15(Sigma Aldrich). 
The cell survival data were plotted as dose-response curves 
with nanoemulsion concentrations. The incubation time was 
24 hours, after which the medium was replaced with growth 
medium after washing of cells using phosphate-buffered 
saline. After 24 hours of incubation, 25 µL of MTT dye 
was added to each well and the cells were incubated for a 
further three hours at 37°C. Then the medium was removed 
and 100 µL dimethyl sulfoxide was added to each well. The 
plates were shaken for 30 seconds and the absorbance was 
recorded at 540 nM using a microplate reader.
Results
composition of the nanoemulsion 
formulations
Prepared as described, cholesteryl oleate had 67% phospho-
lipids, 31% cholesteryl esters, 1% free cholesterol, and 1% 
triglycerides. Cholesteryl stearate had 69% phospholipids, 
29% cholesteryl esters, 1% free cholesterol, and 1% triglycer-
ides. Cholesteryl linoleate had 72% phospholipids, 25% cho-
lesteryl esters, 1% free cholesterol, and 2% triglycerides.
Particle size, ph lipid peroxidation,  
and zeta potential
Figure 2 shows the characteristics of all the   nanoemulsions. 
The sizes of all three preparations were stable during the 
237-day observation period, although cholesteryl stearate 
showed greater size variations than the other two preparations. 
  Cholesteryl stearate nanoemulsions had the greatest particle 
size, as shown in Figure 2A. As shown in   Figure 2B, 
polydispersity of the cholesteryl stearate particles tended to 
decrease over time, whereas polydispersity of both cholesteryl 
oleate and cholesteryl linoleate was unchanged.   Figure 2C 
shows that, during the 237-day observation period, the pH 
of the three nanoemulsion preparations tended to decrease 
over time, but the pH fall of cholesteryl stearate was smaller 
than that occurring for cholesteryl oleate and cholesteryl 
linoleate. As shown in Figure 2D, lipid peroxidation was 
initially greater in cholesteryl linoleate than in   cholesteryl 
oleate and cholesteryl stearate. Subsequently, there was further International Journal of Nanomedicine 2010:5
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  peroxidation in cholesteryl linoleate, whereas   peroxidation 
  markedly increased in cholesteryl stearate, and was unchanged 
over time for cholesteryl oleate.
When measured on day 1, the zeta potential was the same 
in the cholesteryl oleate and cholesteryl stearate   preparations 
(−32.6 ± 2.2 mV and −33.9 ± 2.4 mV,   respectively) and 
tended to decrease on day 210 (−44.0 ± 1.8 mV and 
−38.2 ± 1.6 mV). For cholesteryl linoleate, the zeta poten-
tial on day 1 (−16.0 ± 3.2 mV) was higher than for cholesteryl 
oleate and cholesteryl stearate, and also tended to decrease 
on day 210 (−40.0 ± 3.0 mV).
cell lipid peroxidation in incubates  
with nanoemulsions
As shown in Figure 3A, lipid peroxidation in the HUVEC 
incubates was minimal in the presence of cholesteryl oleate 
and more pronounced by increasing the amounts of choles-
teryl linoleate and cholesteryl stearate. Similar results were 
observed in fibroblasts with minimal peroxidation when 
cholesteryl oleate was added (Figure 3B). In monocytes, per-
oxidation was minimal, not only in the presence of   cholesteryl 
oleate, but also for cholesteryl stearate (Figure 3C). In the 
neoplastic H292 cells, peroxidation was also lower with 
cholesteryl oleate (Figure 3E). In contrast, the highest peroxi-
dation rates with addition of cholesteryl oleate was in mac-
rophage cells (Figure 3D). It is noteworthy that cholesteryl 
linoleate induced the highest cell peroxidation rates with the 
exception of that for the macrophage incubate.
cell uptake in the nanoemulsions
In Figure 4A, it is shown that the cholesteryl oleate uptake 
by HUVEC was markedly greater than that of cholesteryl 
linoleate and cholesteryl stearate, seen from 0.15 mg/mL 
concentration and increasing until 4.14 mg/mL, when an 
apparent plateau was reached. Cholesteryl oleate uptake 
by fibroblasts was also greater than that of the other nano-
emulsions, as shown in Figure 4B. In contrast, uptake of 
the three nanoemulsions by monocytes was similar until 
a concentration of 2.2 mg/mL nanoemulsion lipids was 
reached and, henceforth, the cholesteryl oleate uptake was 
clearly lower than that of the two other nanoemulsion types 
(Figure 4C). With regard to the macrophage cells, uptake 
of both cholesteryl oleate and cholesteryl linoleate was 
negligible at all concentration points, whereas the uptake of 
cholesteryl stearate was continuously increased (Figure 4D). 
Finally, in the neoplastic H292 cell lineage, cholesteryl oleate 
was taken up in greater amounts than cholesteryl linoleate 
and cholesteryl stearate until 4.14 mg/mL, when the uptake 
of all three was equal (Figure 4E).
cell survival upon incubation  
with nanoemulsions
After four hours of incubation with increasing amounts of the 
three nanoemulsion types, HUVEC (IC50 1.15–4.14 mg/mL for 
cholesteryl oleate, nearly 1.15 mg/mL for cholesteryl linoleate, 
and 4.14–5.0 mg/mL for cholesteryl stearate) showed a greater 
survival rate when incubated with   cholesteryl   stearate and International Journal of Nanomedicine 2010:5
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shorter survival with cholesteryl linoleate (Figure 5A). For 
the   neoplastic H292 cells (IC50 . 1.15 mg/mL for   cholesteryl 
oleate, ,4.14 mg/mL for cholesteryl linoleate, and nearly 
5.0 mg/mL for cholesteryl stearate), survival rates were greater 
when incubated with cholesteryl stearate, mainly at higher 
nanoemulsion concentrations (Figure 5B).
Discussion
Lipid nanoparticles have been increasingly perceived as systems 
that can be produced in cost-effective, large-scale quantities,16 
and clinical trials have already been performed that show the 
advantages of these systems. Among the advantages when 
nanoparticles are used as drug carriers is a marked reduction 
in toxicity of the chemotherapeutic agents involved.17,18 This 
highlights the importance of expanding our knowledge of the 
various technologic and biologic aspects of lipid nanoparticles, 
eg, how changes in chemical composition determine size, 
charge, stability, and uptake by different cell lines.19,20
In this study, the cholesteryl stearate nanoemulsion 
showed a greater particle size than the other two   nanoemulsion 
preparations. The greater hydrophobicity of cholesteryl 
  stearate, together with its stereochemical properties, may have 
facilitated the formation of larger particle cores.
The substitution of three different cholesteryl esters 
in the nanoemulsion composition did not affect the stability 
of the nanoemulsion particles, in that all three types showed 
stable particle sizes for approximately eight months without 
addition of antioxidant agents. Presumably, the association of 
drugs with the nanoemulsion structures would be an important 
factor in terms of both the size and stability of the formed 
nanoemulsion-drug particles. In this setting, it is difficult to 
foresee whether cholesteryl stearate composition will also 
favor the formation of larger nanoemulsion-drug particles.
The pH of the cholesteryl linoleate and cholesteryl oleate 
nanoemulsions tended to decrease continuously over the 
eight-month observation period. The decrease in pH was International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Dovepress
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somewhat less for cholesteryl stearate than for the two other 
preparations. The peroxidation of the nanoemulsion lipids 
that occurred in all three preparations over the eight-month 
period might have contributed to the decreased pH.
Lipid peroxidation monitored by TBARS was greater for 
cholesteryl linoleate than for the other preparations from day 1 
onwards, tending to increase further after day 30 of the study 
period. Because polyunsaturated acyl chains are more prone 
to peroxidation than saturated chains, this finding was indeed 
expected. Although peroxidation was low for both cholesteryl 
oleate and cholesteryl stearate soon after manufacture, peroxi-
dation for cholesteryl stearate increased markedly more than 
for cholesteryl oleate after day 30. This would be unexpected 
in view of the chain saturation. Since the nanoemulsions are 
a quaternary system,   interactions with the other components, 
ie, phosphatidylcholine, triolein, and free cholesterol, may 
have accounted for those results. In future studies, a more 
detailed peroxidation profile should be performed, due to the 
limitations of the TBARS method for evaluation of peroxi-
dation status, such as underestimation of total peroxidation 
and lack of discrimination between primary and secondary 
peroxidation products. Mass spectrometry-based and other 
methods also have the ability to distinguish peroxidation of 
the different lipid molecular species specifically.
The zeta potential is a key factor in evaluation of the sta-
bility of colloidal systems. The negative zeta potential value 
would allow prediction of good colloidal stability due to the 
high-energy barrier between particles.21 Thus, zeta potential 
results suggest that all three nanoemulsion preparations were 
stable on day 1 and remained stable at 210 days.
According to the cell uptake results, it is remarkable 
that the cholesteryl oleate nanoemulsion showed the   highest 
uptake rates in three of the five tested cell lines, namely 
HUVEC, fibroblasts, and H292. Cholesteryl oleate had the 
smallest particles 24 hours after manufacture, what suggests 
that particle size can facilitate cell uptake. On the other 
hand, cholesteryl stearate showed the largest particles and 
the greatest uptake rates by the THP-1 lineage differentiated 
in macrophages by PMA. This suggests that larger particles 
are removed by scavenger receptors rather than by lipopro-
tein receptors; the uptake by macrophages of the smaller 
nanoemulsion particles. Cholesteryl oleate and cholesteryl 
linoleate uptake was negligible. In fact, THP-1 macrophages 
show that expression of scavenger receptors and uptake of 
cholesteryl esters by those cells is greater than by primary 
culture macrophages.22
It is worthwhile to point out that uptake of the three 
nanoemulsion types by the monocyte lineage was   several-fold 
greater than that of HUVEC, fibroblasts, and H292 cells. 
Because this cell lineage is of neoplastic origin, it is possible 
that overexpression of lipoprotein receptors associated with 
neoplasias had occurred, leading to the increased uptake. 
In this regard, neoplasia-associated LDL receptor overexpres-
sion can be as high as one hundred times that of normal cells, 
as documented in acute myelocytic leukemia.23,24
The experiment for cell peroxidation showed that 
cholesteryl linoleate induced greater oxidation in HUVEC, 
fibroblasts, monocytes, and H292 cell lines. This is 
conceivably linked with the greater number of double bonds 
in this cholesteryl ester molecular species.25 Interestingly, 
macrophages were the only cell line in which cholesteryl 
oleate nanoemulsions, but not cholesteryl linoleate, produced 
the highest peroxidation rates. Macrophages internalize only 
minimal amounts of cholesteryl oleate nanoemulsions, which 
suggests that uptake of the nanoemulsion is not a precondition 
for peroxidation to occur.
As tested in two cell lines, HUVEC and H292, cell survival 
was longer in incubates with cholesteryl stearate, compared 
with cholesteryl linoleate and cholesteryl oleate. This finding is 
in agreement with those from other investigators26 that showed 
a clear-cut trend for small nanoparticles to be more toxic to 
cells than larger ones. Interestingly, the uptake of cholesteryl 
stearate nanoemulsion by both cell lines was the lowest among 
the three tested nanoemulsions. This would suggest that per-
haps larger lipid uptakes would damage cells.
In the in vivo studies, reduction in toxicity of several 
chemotherapeutic agents, including paclitaxel,5 etoposide,27 
carmustine,4 and daunorubicin,28 incorporated into the nano-
emulsion was remarkable. Those data support the validity of 
lipid nanoemulsion systems as drug vehicles in therapeutics.
Conclusion
Our results showed that all three nanoemulsion prepara-
tions were stable for a long period of time. The cholesteryl 
linoleate nanoemulsion was more prone to lipid peroxidation 
and, in general terms, promoted greater cell peroxidation at 
higher concentrations. Cholesteryl stearate nanoemulsions 
showed high macrophage uptake, probably related to larger 
particle size. Cholesteryl oleate showed greatest uptakes by 
HUVEC, fibroblasts, and H292 cells, with low peroxidation 
levels. The different functional characteristics of   mono-, 
poly-, and saturated cholesteryl esters in terms of size, 
stability, peroxidation, cell uptake, and survival documented 
in this study may provide strategic elements for designing 
study protocols using lipid nanoemulsions for treatment or 
diagnosis of several diseases.International Journal of Nanomedicine
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